Floatz logo

Hu-Mik-Beta-1

T-Cell Large Granular Lymphocytic Leukemia

National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the T-Cell Large Granular Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
CYCLOSPORIN A
Case Comprehensive Cancer Center
Phase 2BB
Cyclophosphamide
Case Comprehensive Cancer Center
Phase 2BB
Busulphan
Ohio State University Comprehensive Cancer Center
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Northwestern University
Phase 2B

View all 49 →

Same molecule, other indications

Hu-Mik-Beta-1 is also rated in:

celiac diseaseDormant
CC
Indicative ·
46 / 100
View asset →
leukemiaDormant
CC
Indicative ·
40 / 100
View asset →
Leukemia, T-Cell Large Granular LymphocyticDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →